ウイルス性肝炎の世界市場レポート 2025年

ウイルス性肝炎の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.2％で199億7,000万米ドルに成長します。予測期間の成長は、治療へのアクセス、公衆衛生法、併用療法、健康公平性への取り組みに起因すると考えられます。予測期間における主な動向には、個別化治療計画、デジタルヘルスツール、疾患モニタリングにおけるai、c型肝炎の微小排除などがあります。

肝炎の有病率の増加は、今後数年間のウイルス性肝炎市場の成長を促進すると予想されます。肝炎とは、様々な感染性ウイルスや非感染性物質によって引き起こされる肝臓感染症を指し、いくつかの健康合併症を引き起こします。A型肝炎、B型肝炎、C型肝炎、D型肝炎、E型肝炎は、肝臓に炎症や損傷を引き起こすウイルス性肝炎の原因ウイルスの一部です。例えば、2024年4月、スウェーデンに本部を置く政府保健機関である欧州疾病予防管理センターは、2022年にEU/EEA加盟30カ国全体で28,855件のB型肝炎ウイルス（HBV）感染症例を報告し、2021年に記録された16,187件から78％の増加を示しました。さらに、2022年の総患者数は28,420人で、人口10万人当たりの粗患者数は8.5人でした。したがって、肝炎の有病率の増加は、ウイルス性肝炎市場の拡大を促進すると思われます。

ウイルス性肝炎市場の強力な成長要因として、研究開発（R&D）の増加が期待されています。ウイルス性肝炎に焦点を当てた研究開発活動は、ワクチン、抗ウイルス薬、診断検査、疫学調査、公衆衛生介入、ゲノム研究、予防戦略、世界ヘルスキャンペーン、臨床試験、重複感染調査などの開発を含む幅広い活動を包含しています。研究開発活動の活発化は、治療アプローチの革新を促進するだけでなく、診断や予防の選択肢を広げます。その結果、臨床試験の数が増え、世界ヘルスへの取り組みが強化され、製薬企業間の競争が激化します。例えば、2022年11月、メルボルンの研究者たちは、mRNAビクトリア活性化プログラムを通じて、今後5年間で170万米ドルの資金を確保しました。この資金提供により、B型肝炎ウイルス感染の治療法を求める先駆的な研究が前進することになります。その結果、研究開発活動の活発化がウイルス性肝炎市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ウイルス性肝炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のウイルス性肝炎市場：成長率分析
• 世界のウイルス性肝炎市場の実績：規模と成長, 2019-2024
• 世界のウイルス性肝炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界ウイルス性肝炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のウイルス性肝炎市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• A型肝炎
• B型肝炎
• C型肝炎
• その他の病気の種類
• 世界のウイルス性肝炎市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝生検
• 血液検査
• 画像検査
• その他の診断
• 世界のウイルス性肝炎市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ウイルス薬
• 手術
• ワクチン
• 免疫調節薬
• その他の治療法
• 世界のウイルス性肝炎市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のウイルス性肝炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界のウイルス性肝炎市場、A型肝炎の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性A型肝炎
• 慢性A型肝炎
• 世界のウイルス性肝炎市場、B型肝炎の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性B型肝炎
• 慢性B型肝炎
• B型肝炎キャリア
• 世界のウイルス性肝炎市場C型肝炎のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性C型肝炎
• 慢性C型肝炎
• 世界のウイルス性肝炎市場、その他の疾患タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• D型肝炎
• E型肝炎

第7章 地域別・国別分析

• 世界のウイルス性肝炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のウイルス性肝炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ウイルス性肝炎市場：競合情勢
• ウイルス性肝炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb
• Astra Zeneca Pharmaceuticals LP
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Co. Ltd.
• Hetero Drugs Ltd.
• Eisai Co. Ltd.
• Boehringer Ingelheim Group
• Sun Pharmaceutical Industries Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ウイルス性肝炎市場2029：新たな機会を提供する国
• ウイルス性肝炎市場2029：新たな機会を提供するセグメント
• ウイルス性肝炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Viral hepatitis encompasses a group of infectious diseases resulting from various viruses (hepatitis A, B, C, D, and E), primarily affecting the liver. The symptoms may vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting, and fever.

The primary types of viral hepatitis diseases include hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a potentially life-threatening liver ailment caused by the hepatitis A virus. Diagnosis is typically achieved through liver biopsy, blood tests, imaging tests, and other diagnostic methods. Treatment options involve antiviral drugs, surgery, vaccines, immune modulator drugs, and others. These treatments can be administered through various routes, including oral and parenteral, and are commonly offered in hospitals, specialty clinics, homecare settings, and other relevant healthcare facilities.

The viral hepatitis market research report is one of a series of new reports from The Business Research Company that provides viral hepatitis market statistics, including viral hepatitis industry global market size, regional shares, competitors with a viral hepatitis market share, detailed viral hepatitis market segments, market trends and opportunities and any further data you may need to thrive in the viral hepatitis industry. This viral hepatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral hepatitis market size has grown steadily in recent years. It will grow from $16.21 billion in 2024 to $16.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.

The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.97 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.

The increasing prevalence of hepatitis is expected to drive the growth of the viral hepatitis market in the coming years. Hepatitis refers to a liver infection caused by various infectious viruses and non-infectious substances, leading to several health complications. Hepatitis A, B, C, D, and E are some of the viruses responsible for viral hepatitis, which causes liver inflammation and damage. For example, in April 2024, the European Centre for Disease Prevention and Control, a government health agency based in Sweden, reported 28,855 cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% increase from the 16,187 cases recorded in 2021. Furthermore, the total number of cases in 2022, which amounted to 28,420, represented a crude rate of 8.5 cases per 100,000 people. Therefore, the growing prevalence of hepatitis will fuel the expansion of the viral hepatitis market.

The increasing volume of research and development (R&D) endeavors is expected to serve as a powerful growth driver for the viral hepatitis market. Research and development initiatives focused on viral hepatitis encompass a wide spectrum of activities, including the development of vaccines, antiviral medications, diagnostic tests, epidemiological studies, public health interventions, genomic research, prevention strategies, global health campaigns, clinical trials, and investigations into co-infections. The upsurge in R&D activities not only fosters innovation in treatment approaches but also expands the array of options for diagnosis and prevention. This, in turn, leads to a higher number of clinical trials, stronger global health initiatives, and heightened competition among pharmaceutical companies. For instance, in November 2022, researchers in Melbourne secured funding of $1.7 million for the next five years through the mRNA Victoria Activation Program. This funding is set to advance their pioneering work in the quest for a cure for hepatitis B virus infection. Consequently, the escalation in the number of research and development activities is a driving force behind the growth of the viral hepatitis market.

Prominent companies active in the viral hepatitis market are dedicated to advancing the development of new drugs to reinforce their position within the market. The pursuit of drug development and innovation serves to enrich scientific understanding by shedding light on disease mechanisms, thus expediting the creation of novel treatments. For instance, in November 2022, Gilead Sciences Inc., a biopharmaceutical company based in the United States, disclosed the FDA's granting of the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. These tablets are designed for once-daily administration to address chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. The approval for Vemlidy's utilization in this specific group of pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.

In November 2023, GSK plc, a pharmaceuticals company based in the U.K., acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. With the acquisition of the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug, GSK aims to enhance its portfolio and reinforce its position in the chronic hepatitis B treatment space by adding a new and potentially valuable therapy. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, is known for developing treatments for infectious diseases, including chronic hepatitis B.

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the viral hepatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The viral hepatitis market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral hepatitis market also includes the sales of treatments such as vaccines and medication. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Hepatitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral hepatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral hepatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral hepatitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
• 2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
• 3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
• 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A
• 2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier
• 3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C
• 4) By Other Disease Types: Hepatitis D; Hepatitis E
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Co; F Hoffmann-La Roche AG; Merck & Co.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Viral Hepatitis Market Characteristics

3. Viral Hepatitis Market Trends And Strategies

4. Viral Hepatitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Viral Hepatitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Viral Hepatitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Viral Hepatitis Market Growth Rate Analysis
• 5.4. Global Viral Hepatitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Viral Hepatitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Viral Hepatitis Total Addressable Market (TAM)

6. Viral Hepatitis Market Segmentation

• 6.1. Global Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Other Disease Types
• 6.2. Global Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liver Biopsy
• Blood Tests
• Imaging Tests
• Other Diagnosis
• 6.3. Global Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Drugs
• Surgery
• Vaccine
• Immune Modulator Drugs
• Other Treatments
• 6.4. Global Viral Hepatitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.5. Global Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis A, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis A
• Chronic Hepatitis A
• 6.7. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis B
• Chronic Hepatitis B
• Hepatitis B Carrier
• 6.8. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis C, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis C
• Chronic Hepatitis C
• 6.9. Global Viral Hepatitis Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis D
• Hepatitis E

7. Viral Hepatitis Market Regional And Country Analysis

• 7.1. Global Viral Hepatitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Viral Hepatitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Viral Hepatitis Market

• 8.1. Asia-Pacific Viral Hepatitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Viral Hepatitis Market

• 9.1. China Viral Hepatitis Market Overview
• 9.2. China Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Viral Hepatitis Market

• 10.1. India Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Viral Hepatitis Market

• 11.1. Japan Viral Hepatitis Market Overview
• 11.2. Japan Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Viral Hepatitis Market

• 12.1. Australia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Viral Hepatitis Market

• 13.1. Indonesia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Viral Hepatitis Market

• 14.1. South Korea Viral Hepatitis Market Overview
• 14.2. South Korea Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Viral Hepatitis Market

• 15.1. Western Europe Viral Hepatitis Market Overview
• 15.2. Western Europe Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Viral Hepatitis Market

• 16.1. UK Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Viral Hepatitis Market

• 17.1. Germany Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Viral Hepatitis Market

• 18.1. France Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Viral Hepatitis Market

• 19.1. Italy Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Viral Hepatitis Market

• 20.1. Spain Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Viral Hepatitis Market

• 21.1. Eastern Europe Viral Hepatitis Market Overview
• 21.2. Eastern Europe Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Viral Hepatitis Market

• 22.1. Russia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Viral Hepatitis Market

• 23.1. North America Viral Hepatitis Market Overview
• 23.2. North America Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Viral Hepatitis Market

• 24.1. USA Viral Hepatitis Market Overview
• 24.2. USA Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Viral Hepatitis Market

• 25.1. Canada Viral Hepatitis Market Overview
• 25.2. Canada Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Viral Hepatitis Market

• 26.1. South America Viral Hepatitis Market Overview
• 26.2. South America Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Viral Hepatitis Market

• 27.1. Brazil Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Viral Hepatitis Market

• 28.1. Middle East Viral Hepatitis Market Overview
• 28.2. Middle East Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Viral Hepatitis Market

• 29.1. Africa Viral Hepatitis Market Overview
• 29.2. Africa Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Viral Hepatitis Market Competitive Landscape And Company Profiles

• 30.1. Viral Hepatitis Market Competitive Landscape
• 30.2. Viral Hepatitis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Viral Hepatitis Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi SA
• 31.3. Bristol-Myers Squibb
• 31.4. Astra Zeneca Pharmaceuticals LP
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Gilead Sciences Inc.
• 31.8. Viatris Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Astellas Pharma Inc.
• 31.11. Daiichi Sankyo Co. Ltd.
• 31.12. Hetero Drugs Ltd.
• 31.13. Eisai Co. Ltd.
• 31.14. Boehringer Ingelheim Group
• 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Viral Hepatitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral Hepatitis Market

34. Recent Developments In The Viral Hepatitis Market

35. Viral Hepatitis Market High Potential Countries, Segments and Strategies

• 35.1 Viral Hepatitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Viral Hepatitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Viral Hepatitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer